Citations

Clear

14 citation(s) found for "Patel, Amit".

Ambulatory reflux monitoring for diagnosis of gastro‐esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group
Roman, Sabine , Gyawali, C. Prakash , Savarino, Edoardo , Wu, Justin C. Y. , Vela, Marcelo F. , Tatum, Roger P. , Fox, Mark , Pandolfino, John E. , Bredenoord, Albert J. , group, the GERD consensus, Tack, Jan , Penagini, Roberto , Mion, François , Bor, Serhat , Patel, Amit , Cicala, Michele , Bortoli, Nicola de , Azpiroz, Fernando , Roman, S , Gyawali, C P , Yadlapati, Rena , Zerbib, Frank , Tutuian, Radu I. , Sifrim, Daniel , Keller, Jutta , group, the GERD consensus, Patel, A , Penagini, Roberto , Tack, Jan , Bor, Serhat , de Bortoli, Nicola , Savarino, Edoardo

Mayo Clinic

Neurogastroenterology & Motility | March 31, 2017 | Volume: 29 | Issue: 10 | Pages: 1-15

10.1111/nmo.13067 | PMID 28370768 Get It

AbstractBackgroundAn international group of experts evaluated and revised recommendations for ambulatory reflux monitoring for the diagnosis of gastro‐esophageal reflux disease (GERD).MethodsLiterature search was focused on indications and technical recommendations for GERD testing and phenotypes definitions. Statements were proposed and discussed during several structured meetings.Key ResultsReflux testing should be performed after cessation of acid suppressive medication in patients with a low likelihood of GERD. In this setting, testing can be either catheter‐based or wireless pH‐monitoring or pH‐impedance monitoring. In patients with a high probability of GERD (esophagitis grade C and D, histology proven Barrett's mucosa >1 cm, peptic stricture, previous positive pH monitoring) and persistent symptoms, pH‐impedance monitoring should be performed on treatment. Recommendations are provided for data acquisition and analysis. Esophageal acid exposure is considered as pathological if acid exposure time (AET) is greater than 6% on pH testing. Number of reflux episodes and baseline impedance are exploratory metrics that may complement AET. Positive symptom reflux association is defined as symptom index (SI) >50% or symptom association probability (SAP) >95%. A positive symptom‐reflux association in the absence of pathological AET defines hypersensitivity to reflux.Conclusions and InferencesThe consensus group determined that grade C or D esophagitis, peptic stricture, histology proven Barrett's mucosa >1 cm, and esophageal acid exposure greater >6% are sufficient to define pathological GERD. Further testing should be considered when none of these criteria are fulfilled.
Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction
Murtagh, Gillian , Laffin, Luke J. , Patel, Kershaw V. , Bonham, Catherine A. , Yu, Zoe, Addetia, Karima , El‐Hangouche, Nadia , Maffesanti, Francesco, Mor‐Avi, Victor , Sweiss, Nadera , Beshai, John F., Lang, Roberto M. , Patel, Amit R. , Patel, Amit , Hogarth, D. Kyle

Mayo Clinic

Echocardiography | September 28, 2016 | Volume: 33 | Issue: 9 | Pages: 1344-1352

10.1111/echo.13281 | PMID 27677642 Get It

BackgroundCardiac infiltration is an important cause of death in sarcoidosis. Transthoracic echocardiography (TTE) has limited sensitivity for the detection of cardiac sarcoidosis (CS). Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) is used to diagnose CS but has limitations of cost and availability. We sought to determine whether TTE‐derived global longitudinal strain (GLS) may be used to identify individuals with CS, despite preserved left ventricular ejection fraction (LVEF), and whether abnormal GLS is associated with major cardiovascular events (MCE).MethodsWe studied 31 patients with biopsy‐proven extra‐cardiac sarcoidosis, LVEF>50% and LGE on CMR (CS+ group), and 31 patients without LGE (CS− group), matched by age, sex, and severity of lung disease. GLS was measured using vendor‐independent speckle tracking software. Parameters of left and right ventricular systolic and diastolic function were also studied. Receiver‐operating characteristic curves were used to identify GLS cutoff for CS detection, and Kaplan–Meier plots to determine the ability of GLS to predict MCE.ResultsLGE was associated with reduced GLS (−19.6±1.9% in CS− vs −14.7±2.4% in CS+, P<.01) and with reduced E/A ratio (1.1±0.3 vs 0.9±0.3, respectively, P =.01). No differences were noted in other TTE parameters. GLS magnitude inversely correlated with LGE burden (r=−.59). GLS cutoff of −17% showed sensitivity and specificity 94% for detecting CS. Patients who experienced MCE had worse GLS than those who did not (−13.4±0.9% vs −17.7±0.4%, P=.0003).ConclusionsCS is associated with significantly reduced GLS in the presence of preserved LVEF. GLS measurements may become part of the TTE study performed to screen for CS.
Autologous CD34 + Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
Henry, Timothy D. , Schaer, Gary L. , Povsic, Thomas J. , Davidson, Charles J., Lee, Joon Sup, Bass, Theodore A., Mendelsohn, Farrell O., Fortuin, F. David , Pepine, Carl J. , Patel, Amit N. , Riedel, Norbert, Junge, Candice, Hunt, Andrea S, Kereiakes, Dean J. , Harrington, Robert A. , Schatz, Richard A. , Losordo, Douglas W. , Traverse, Jay H. , Costa, Marco Antonio , White, Christopher J.

Mayo Clinic

Cell Transplantation | May 5, 2016 | Volume: 25 | Issue: 9 | Pages: 1701-1711

10.3727/096368916x691484 | PMID 27151378 Get It

An increasing number of patients have refractory angina despite optimal medical therapy and are without further revascularization options. Preclinical studies indicate that human CD34 + stem cells can stimulate new blood vessel formation in ischemic myocardium, improving perfusion and function. In ACT34-CMI ( N = 167), patients treated with autologous CD34 + stem cells had improvements in angina and exercise time at 6 and 12 months compared to placebo; however, the longer-term effects of this treatment are unknown. ACT34 was a phase II randomized, double-blind, placebo-controlled clinical trial comparing placebo, low dose (1 × 10 5 CD34/kg body weight), and high dose (5 × 10 5 CD34/kg) using intramyocardial delivery into the ischemic zone following NOGA ® mapping. To obtain longer-term safety and efficacy in these patients, we compiled data of major adverse cardiac events (MACE; death, myocardial infarction, acute coronary syndrome, or heart failure hospitalization) up to 24 months as well as angina and quality of life assessments in patients who consented for 24-month follow-up. A total of 167 patients with class III–IV refractory angina were randomized and completed the injection procedure. The low-dose-treated patients had a significant reduction in angina frequency ( p = 0.02, 0.035) and improvements in exercise tolerance testing (ETT) time ( p = 0.014, 0.017) compared to the placebo group at 6 and 12 months. At 24 months, patients treated with both low-and high-dose CD34 + cells had significant reduction in angina frequency ( p = 0.03). At 24 months, there were a total of seven deaths (12.5%) in the control group versus one (1.8%) in the low-dose and two (3.6%) in the high-dose ( p = 0.08) groups. At 2 years, MACE occurred at a rate of 33.9%, 21.8%, and 16.2% in control, low-, and high-dose patients, respectively ( p = 0.08). Autologous CD34 + cell therapy was associated with persistent improvement in angina at 2 years and a trend for reduction in mortality in no-option patients with refractory angina.
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction
Murtagh, Gillian , Laffin, Luke J. , Beshai, John F., Maffessanti, Francesco , Bonham, Catherine A. , Yu, Zoe, Addetia, Karima , Mor‐Avi, Victor , Sweiss, Nadera , Lang, Roberto M. , Patel, Amit R. , Patel, Amit V, Mor-Avi, Victor, Moss, Joshua D, Hogarth, D. Kyle , Sweiss, Nadera J, Patel, Amit , Moss, Joshua D.

Mayo Clinic

Circulation: Cardiovascular Imaging | January 14, 2016 | Volume: 9 | Issue: 1 | Pages: No page available

10.1161/circimaging.115.003738 | PMID 26763280 Get It

Background— Cardiac sarcoidosis is associated with an increased risk of heart failure and sudden death, but its risk in patients with preserved left ventricular ejection fraction is unknown. Using cardiovascular magnetic resonance in patients with extracardiac sarcoidosis and preserved left ventricular ejection fraction, we sought to (1) determine the prevalence of cardiac sarcoidosis or associated myocardial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their risk of death/ventricular tachycardia (VT), and (3) identify imaging-based covariates that predict who is at greatest risk of death/VT. Methods and Results— Parameters of left and right ventricular function and LGE burden were measured in 205 patients with left ventricular ejection fraction >50% and extracardiac sarcoidosis who underwent cardiovascular magnetic resonance for LGE evaluation. The association between covariates and death/VT in the entire group and within the LGE+ group was determined using Cox proportional hazard models and time-dependent receiver–operator curves analysis. Forty-one of 205 patients (20%) had LGE; 12 of 205 (6%) died or had VT during follow-up; of these, 10 (83%) were in the LGE+ group. In the LGE+ group (1) the rate of death/VT per year was >20× higher than LGE− (4.9 versus 0.2%, P <0.01); (2) death/VT were associated with a greater burden of LGE (14±11 versus 5±5%, P <0.01) and right ventricular dysfunction (right ventricular EF 45±12 versus 53±28%, P =0.04). LGE burden was the best predictor of death/VT (area under the receiver-operating characteristics curve, 0.80); for every 1% increase of LGE burden, the hazard of death/VT increased by 8%. Conclusions— Sarcoidosis patients with LGE are at significant risk for death/VT, even with preserved left ventricular ejection fraction. Increased LGE burden and right ventricular dysfunction can identify LGE+ patients at highest risk of death/VT.